The stimulation of the immune system, in order to generate an attack against cancer cells, similarly to that which occurs in infectious disease, has long been matter of interest in oncology; however, only limited success has been achieved, with different treatment strategies tested in recent years. The development of new immune checkpoint inhibitors is currently changing this scenario, and immunotherapy is becoming a real choice among traditional cytotoxic treatments to fight cancer. Recent reports have shown efficacy and safety with the use of pembrolizumab, nivolumab, and ipilimumab for the treatment of different neoplasms, especially melanoma. In this article, we propose a review of the mechanisms of action involved in cancer immunology, the response evaluation of immunotherapies, and its toxicity profile, as well as a summary of the main clinical trials that led to the adoption of these new drugs for melanoma treatment.
INTRODUCTION
The importance of the immune system in fighting cancer has been studied since the 19th century, when, in 1891, the American surgeon William Coley described his experiment with the intratumoral inoculation of Streptococcus pyogenes and Serratia marcescens, expecting to reproduce a rare spontaneous sarcoma remission case observed after the patient had had erysipelas. 1 The subject continued to raise interest within the scientific community. However, despite the rare exceptions, such as the case of intravesical treatment of a superficial bladder neoplasm with BCG, for a long period of time, the complex nature of the immune system action mechanisms limited the development of other effective therapies for clinical use. 2 This scenario more recently has been revolutionized, especially after the approval for the clinical use of immune checkpoint inhibitors in melanomas and other tumor types.
The neoplastic cells' acquisition of the capability to evade the immune system -as well as their ability to subvert it to their advantage -is one of the "milestones" for the development of neoplasms. 3 Therefore, it is acknowledged that cancer is capable of "editing" the immune system, and the neoplastic cells need to acquire the capability of "escaping" the immune system in order to develop,
given that the immune system would be capable of "eliminating" these sick cells. This theory also suggests that there is a "balance" between the forces that lead to the disease's elimination and those that lead to acquiring the immune system's evasion ability. This intermediate period would at least partially explain the mechanism by which some types of neoplasms may remain stable in their growth over long periods of time, or even the mechanism that leads to late recurrences after adjuvant treatments, when micrometastases remain clinically dormant for several years. 4 The immune system consists of two different cell types and by cells at different maturation phases in a complex interaction in which communication is performed by means of stimuli sent with the secretion of cytokines, and by the activation of membrane receptors in the contact between the cells. The immune system is subdivided into the innate immune system and the adaptive immune system, and their main difference is that the adaptive immune system is capable of specifically identifying a given aggressor (or antigen) and of maintaining this identification memory for a quick immune response in case of new exposure to the same agent. The innate immune system, however, has common abilities among the different organisms, and it is considered our first line of defense. Both the innate and the adaptive systems are involved in fighting cancer, and the different cell types play specific roles. molecules may present, to the CTL, the neo-antigens generated from proteins expressed by mutated genes in the carcinogenesis process (because they are proteins whose structure had been altered, they will be identified by the immune system as being foreign) and, thus, trigger the cytotoxicity process against cancer. For this reason, the higher the number of mutations (or "mutational load") in a given tumor, the greater the potential benefit with immunological therapies. 5 Similarly, the greater CD8+ T lymphocyte infiltration in tumors seems to be associated with the best clinical outcomes, given that they may represent an exacerbated cytotoxicity process against cancer. 6 The identification process of antigens linked to MHC I molecules by CTL, with the consequent cytotoxicity induction, is called the cell immune system effector phase, which, similar to the initiation phase, is regulated by other molecules' stimuli on immune The manipulation of T lymphocytes in order to make them reactive to specific antigens, and therefore stimulate the antitumoral response, is among the promising immunotherapy strategies. The 
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Anti-PD-1 antibodies
Pembrolizumab is one of the most studied anti-PD-1 monoclonal antibodies in metastatic melanoma, and has been evaluated both in monotherapy and in combination with anti-CTLA-4 block.
In a phase I study, 655 patients -among which one third had previously been treated with chemotherapy or immunotherapy -were allocated in four cohorts, using pembrolizumab at different dosages (10 mg/kg every two weeks; 10 mg/kg every three weeks or 2 mg/kg every two weeks). The objective response rate (ORR) was 33%, with a progression-free survival rate (PFS) at 12, 24, and 36 months of 35%, 28%, and 21%, respectively. In the end, the overall survival rate (OS) at 12, 24, and 36 months was 73%, 50%, and 40%.
There was no ORR difference between those who had previously been exposed to anti-CTLA-4 block and those who had not, nor between wild or mutated V600 tumors. The absence of PD-L1 tumoral expression has not proven to be a beneficial absence marker with pembrolizumab. The most common adverse effects were fatigue, pruritus, exanthem, diarrhea, and arthralgia. Nevertheless, only 14% of the patients exhibited grade 3 or 4 adverse effects. [16] [17] [18] In the phase II controlled study KEYNOTE-002, 540 patients were randomized after progression with ipilimumab to receive pembrolizumab (2 mg/kg or 10mg/kg every three weeks) or chemotherapy at the researcher's discretion (carboplatin with paclitaxel or monotherapy with paclitaxel, dacarbazine, or temozolomide). The primary outcome was reached with a statistically significant difference in PFS in six months (34%, 38%, and 16% in the sub-groups treated with pembrolizumab 2 mg/kg, 10 mg/kg or chemotherapy).
The ORR rates were 21%, 26%, and 4%, respectively. The toxicity profile was similar to that observed in previous studies, with grade 3 to 5 adverse effects, in 11% to 14% of the patients treated with pembrolizumab, and 26% of patients treated with chemotherapy.
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Pembrolizumab was also compared to ipilimumab, a treatment considered to be standard at the time, in the phase III study KEYNOTE-006. The study randomized 834 patients between pembrolizumab (10 mg/kg every three or two weeks, continued for two years) and ipilimumab 3 mg/kg every three weeks for four doses. Both primary outcomes (progression-free survival and overall survival) reached a statistically significant benefit, comparing the use of pembrolizumab at different doses and chemotherapy. Therefore, the PFS in 12 months was 39% and 38% versus 19%, while in 24 months, it was 31% and 28% versus 14% (hazard ratio [HR] 0.68 and 0.68, respectively, for pembrolizumab every two or three weeks versus chemotherapy), and OS in a year was 74% and 68% versus 59% and, in two years, was 55% and 55% versus 43% (HR 0.61 and 0.69 for both comparisons). In addition, grade 3 to 5 adverse events were less frequent on the arms with the use of pembrolizumab (13% and 10% versus 20% in patients treated with chemotherapy). 20 Nivolumab is a second anti-PD-1 monoclonal antibody, developed to inhibit immune checkpoints, which has proven to be useful in advanced melanoma treatment. In an initial phase I/ II study, 107 patients were exposed to different nivolumab doses between 0.1 and 10 mg/kg every two weeks for up to 96 weeks.
The median OS was 17 months with a global response of 32% of the patients. The OS rates in one, two, three, four, and five years were 63%, 48%, 42%, 35%, and 34%, respectively, which led to the development of the CheckMate 066 study. 21 In this phase III study, 418
patients with metastatic melanoma and wild BRAF, and who had not received prior treatment were included for the randomization between nivolumab 3 mg/kg and dacarbazine 1,000 mg/m², both 
Anti-CTLA-4 antibody
Ipilimumab is an anti-CTLA-4 monoclonal antibody and was the first immune checkpoint inhibitor to be approved for clinical use. However, with the advent of anti-PD-1 therapies, ipilimumab has been losing its spotlight position due to its unfavorable toxicity profile and lower antitumoral activity. In two phase III studies, ipilimumab revealed a significant OS increase, which was associated with a benefit plateau after three years of treatment. [24] [25] [26] The first published study randomized 676 patients after failure in the previous treatment to received ipilimumab monotherapy, ipilimumab associated with gp100 vaccine, or gp100 in monotherapy. A statistically significant benefit was reported in the sub-groups treated with ipilimumab: the OS rates in 24 months were 24%, 22%, and 14%, with ORR rates of 10.9%, 5.7%, and 1.5%, respectively. 24 The second study randomized 502 patients who had never received prior treatment into two groups: dacarbazine with ipilimumab and dacarbazine with placebo. The results were favorable to the ipilimumab arm, the median OS was 11.2 versus 9.1 months, with OS in a year of 47% versus 36% and OS in five years of 18% versus 9%.
Although only a minority of patients has presented a complete response (CR), such responses appear to have been long-lasting in many of them. 25, 26 Ipilimumab was studied at different doses. However, the approved dose for clinical use was based on the phase III study, with 3 mg/kg every three weeks for four doses.
24
Ipilimumab was also approved in the USA as an adjuvant treatment of high-risk stage III melanoma, based on the results of a study that randomized 951 patients between placebo and ipilimumab at 10 mg/kg for four doses every three weeks, continuing with monthly applications for up to three years. This study revealed significant benefits in the relapse-free survival, with a relapse median of 26 versus 17 months, and a three-year relapse rate of 46.5% versus 34.8%. However, the treatment was associated with an expressive toxicity profile with 90% of the patients presenting immune-related adverse effects, including 42% of degree 3 to 4 events, in addition to five deaths related to the drug. 27 Data on this strategy's benefit in global survival, benefit equivalence with an ipilimumab dose reduction to 3 mg/kg (as is the case of the approved dose for advanced disease treatment) or the direct comparison with adjuvant therapy, with high interferon doses being actively researched.
Combination therapy and sequential treatment
The anti-PD-1 and anti-CTLA-4 block combination exhibit an increase in the tumoral activity. However, this strategy expressively increased the toxicity associated with the treatment. 28 In addition; data on the benefits to overall survival with this approach
have not yet been established. Therefore, phase III definitive results are required to determine if the combination may become the new treatment standard.
The most solid results obtained so far, for a combined block in advanced melanoma, were obtained in the double-blind phase III CheckMate 067, in which 945 patients who had not received prior treatment were randomized to receive nivolumab at 1 mg/ kg associated with ipilimumab 3 mg/kg every three weeks for four doses, followed by nivolumab 3 mg/kg every two weeks; nivolumab 3 mg/kg every two weeks, or ipilimumab 3 mg/kg every three weeks for four doses. Partial results, with a median follow-up of 21 months, have been published, and the PFS median for the combination of monodrug nivolumab and monodrug ipilimumab was 11.5, 6.9, and 2.9 months, with a response rate of 58%, 44%, and 19%, and a degree 3 or 4 toxicity of 55%, 16%, and 27%, respectively.
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Data on sequential blockage with anti-CTLA-4 and anti-PD-1 were obtained with a phase II study involving 140 patients, in which the induction scheme with nivolumab, 3 mg/kg every two weeks during six applications, followed by ipilimumab 3 mg/ kg every three weeks for four cycles, or the reverse sequence, were compared. After this induction scheme, both the cohorts received nivolumab at 3 mg/kg every two weeks up to the onset of disease progression. The frequency of grade 3 to 5 adverse events was higher in the nivolumab-ipilimumab group, compared to ipilimumab-nivolumab (50% versus 43%). With a median follow-up of 18.6 months, the response rate was higher in the nivolumab-ipilimumab sequence, 41% versus 20%. 30 Apparently, this strategy does not seem to be less toxic or more powerful than the combined scheme.
FACTORS PREDICTING RESPONSE
The new immunotherapies have brought important advances in the treatment of patients with melanoma or other neoplasms in advanced stages. However, these treatments were associated with potentially severe side effects, with a high financial cost, and not all patients will present antitumoral response with clinical benefits.
Therefore, an issue to be resolved is the selection of patients with a higher chance of obtaining gains with these new therapies.
The most extensively explored response biomarker candidate for immune checkpoint inhibitor is the PD-L1 immuno-histochemical expression. As previously mentioned, the interaction between PD-L1 and the PD-1 membrane receptor -present in T-lymphocytes and in other immune system cells -is responsible for limiting both the initiation phase and the effector phase of the immune response, given that PD-L1 is constitutively expressed in the APC and in the healthy cells of the organism. Therefore, the PD-1/ PD-L1 complex is part of the normal immunological tolerance process for inhibiting autoimmunity, but may also be involved in the cancer immunological resistance when there is PD-L1 hyperexpression by the neoplastic cells. However, the interaction between the tumor and the immune system also involves other mechanisms that are not fully understood, and the absence of TIL, observed in some tumors, seems to be a reflection of this process, because it represents a tumor with worse prognosis and better resistance to the immunological attack. 31 Several methodological issues are involved in the PD-L1
analysis as a biomarker, from the choice of tissue to be evaluated or the antibody used in marking the definition of positivity criteria. The lack of PD-L1 expression appeared to predict the absence of response in a preliminary phase I study, which evaluated the anti-PD-1 treatment with nivolumab in different types of neoplasm. 32 However, subsequent studies were not capable of determining an expression level from which the patients no longer present benefits with immune checkpoints inhibitors. 23, 33 Other possible response biomarkers are also being studied, as is the case of the tumoral load quantification or the DNA repair enzyme deficiency (for generating genetic instability and increasing the tumoral load); however, neither of these tests has presented definite results thus far. These tests should not be used to exclude potential candidates to undergo immunotherapies.
ASSESSMENT OF IMMUNOTHERAPY RESPONSE
The action mechanism of the chemotherapy agents is the direct cytotoxicity to neoplastic cells, and the treatment response may be measured by the tumoral volume reduction within a few weeks after its administration. However, the antitumoral effect of immunological therapies includes more sophisticated cell death induction mechanisms, and it involves the recruitment of different cells in the immune system. These cells infiltrated in the tumoral microenvironment are directly or indirectly responsible for the cytotoxicity effect. In addition, these cells may acquire the ability to perpetuate the antitumoral response, even after exposure to immunotherapy has been discontinued. Thus, the criteria used to evaluate the response of cytotoxic agents -such as RECIST -may not be capable of correctly interpreting the benefit generated with checkpoint inhibitors or other immunological agents. 34, 35 Some response patterns generated with immunotherapy may be expressively different from those observed with cytotoxic agents. Therefore, some patients may present significant clinical benefits without meeting objective response criteria, and they may stabilize the disease for long periods. An expressive tumoral regression -including complete response -may be reached from a slow, but progressive, reduction of the neoplasm. This improvement may be maintained even after the treatment has been discontinued. In addition, in certain situations, a temporary and initial increase in the disease -even with the appearance of new lesions -may be observed before the response to the treatment is established. This "pseudoprogression" may be explained by the worsening of the disease prior to the start of drug action. It may also be caused by the infiltration of inflammatory cells in the tumoral tissue, accompanied by edema or not, which makes lesions more easily identifiable in image tests. In this scenario, it is important to avoid early therapy interruption. However, a rapid progression scenario or the presence of clinical deterioration normally indicates a primary resistance to treatment. 34 The immune response criteria were proposed in the attempt to standardize the interpretation of image tests after the new immunological treatments. 34 Thus, the concept of pseudoprogression was considered to be a form of response, and the measurement of lesions that appeared after the start of treatment -which, according to RECIST or to the World Health Organization criteria, define the disease progression -is now added to the measurement of the target lesions in calculating the "tumoral load". According to the associated immune response criteria, the increase of at least 25% in the tumoral load defines disease progression; the reduction of 50%
or more is considered a partial response; an intermediate variation in the tumoral load is classified as a stable disease; and the complete resolution of all lesions is understood as the complete response.
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CONCLUSION
The different types of treatment that act based on immune system modulation to fight cancer are not a totally new concept.
However, the development of strategies capable of generating a more specific response against neoplastic cells, with lower toxicity to the organism, ensure these new strategies earn a growing importance among the different oncological treatment options. A more detailed understanding of the specificities of new immunotherapies is important for all medical specialties involved in melanoma treatment, as these drugs have their unique action mechanisms, with unusual response patterns and toxicity profiles, when compared to traditional cytotoxic drugs. The selection of patients that are candidates to the treatment should be a responsibility shared by all participants in this multidisciplinary team. q
